Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8279963 | 0.79 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1TSHRLMNA | |
| SCHEMBL11351147 | 0.78 | MEN1 (0.44) | MEN1KMT2AALDH1A1TSHRCYP2C9 | |
| SCHEMBL6489591 | 0.78 | MCL1 (0.39) | MCL1HSD17B10HTT | |
| SCHEMBL28504677 | 0.76 | MCL1 (0.44) | MEN1KMT2AMCL1LMNAALOX15 | |
| SCHEMBL9194192 | 0.74 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1TSHRCYP2C9 | |
| SCHEMBL5079020 | 0.72 | MCL1 (0.52) | ALDH1A1MCL1GAA | |
| SCHEMBL5454379 | 0.71 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1TSHRCYP2C9 | |
| SCHEMBL12016293 | 0.71 | ALOX15 (0.48) | MEN1KMT2AALDH1A1LMNAHSD17B10 | |
| SCHEMBL4403350 | 0.71 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1TSHRMCL1 | |
| SCHEMBL1405183 | 0.70 | LMNA (0.48) | MEN1KMT2AALDH1A1TSHRMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930107-B2 | 6-azauracil derivatives as thyroid receptor ligands | PFIZER INC. (US) | 2005-08-16 | — | — | US | disclosed |
| EP-1088819-B1 | 6-azauracil derivatives as thyroid receptor ligands | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6787652-B1 | LOWERING LIPIDS AND SERUM CHOLESTEROL WITHOUT GENERATING ADVERSE CARDIAC EFFECTS; 4,5-DIHYDRO-3,5-DIOXO-1,2,4-TRIAZINE DERIVATIVES | PFIZER, INC. | 2004-09-07 | — | — | US | disclosed |
| US-20040157844-A1 | 6-azauracil derivatives as thyroid receptor ligands | DOW ROBERT L (US) | 2004-08-12 | — | — | US | disclosed |
| EP-1088819-A2 | 6-azauracil derivatives as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-0330041-B1 | Substituted 1,2,4-trazine diones, process for their synthesis and their use | BAYER AG (DE) | 1994-04-13 | — | — | EP | disclosed |
| US-5256631-A | Substituted 1,2,4-triazinediones, and their use | BAYER AKTIENGESELLSCHAFT (DE) | 1993-10-26 | — | — | US | disclosed |
| US-5214043-A | Controlling parasitic protozoa and fish parasites | BAYER AKTIENGESELLSCHAFT (DE) | 1993-05-25 | — | — | US | disclosed |
| US-5114938-A | Antiprotozoa agents and parasiticides | BAYER AKTIENGESELLSCHAFT (DE) | 1992-05-19 | — | — | US | disclosed |
| EP-0476439-A1 | Substituted 1,2,4-triazindiones, method for their preparation, intermdiates for it and their use | BAYER AG (DE) | 1992-03-25 | — | — | EP | disclosed |
| US-4968795-A | PARASITICIDES, ANTIPROTOZOA AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | disclosed |
| EP-0377903-A2 | Substituted hexahydro-1,2,4-triazine diones, processes for their preparation, intermediates and their use | BAYER AG (DE) | 1990-07-18 | — | — | EP | disclosed |
| US-4935423-A | Antiprotozoa agent | BAYER AKTIENGESELLSCHAFT (DE) | 1990-06-19 | — | — | US | disclosed |
| EP-0330041-A2 | Substituted 1,2,4-trazine diones, process for their synthesis and their use | BAYER AG (DE) | 1989-08-30 | — | — | EP | disclosed |
| US-4272535-A | 2,4-[1H,3H,5H]-(1)-Benzopyrano-[2,3-d]-pyrimidinediones and their use as anti-allergy agents | SCHERING CORPORATION (US) | 1981-06-09 | — | — | US | disclosed |
| EP-0008277-A1 | Benzopyrano derivatives, pharmaceutical compositions containing them and processes for preparing the compounds and compositions | Technobiotic Ltd. (CH) | 1980-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157844-A1 | 6-azauracil derivatives as thyroid receptor ligands | TSHR, THRA, THRB | MEN1 1028/4885KMT2A 2850/4885ALDH1A1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.